Ibrance may be effective for post-menopausal breast cancer patients
Currently, Ibrance is not prescribed for menopausal or post-menopausal women. The U.S. Food and Drug Administration (FDA) has granted priority review for a supplemental New Drug Application for Ibrance to expand its approved uses. Action on the application is expected to take place in April 2016.
“We look forward to continuing to work with the FDA to add the robust Phase 3 data set from the PALOMA-3 trial to the available data in the Ibrance label,” Liz Barrett, global president of Pfizer Oncology, said. “Since FDA approval in February, more than 18,000 women have been treated with Ibrance by approximately 5,000 prescribers in the U.S. With approval of this indication, we hope to expand the role of Ibrance in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer and to serve even more patients with this first-in-class medicine."
More information about Ibrance and Pfizer's other therapies can be found online at the company's home page. Pfizer was founded by cousins Charles Pfizer and Charles Erhart in 1849.
Organizations in this story
Pfizer 235 E 42nd St New York, NY 10017-5703